Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Bio2Brain

Financiado

Nose to Brain Delivery of Biopharmaceutics for the therapy of central nervous sy...

Nose to Brain Delivery of Biopharmaceutics for the therapy of central nervous system diseases A design based approach for efficient drug delivery systems Bio2Brain aims to create a trans-European network of industrially oriented specialists fully trained and experienced, a significant driving force in innovating novel technologies to deliver biopharmaceuticals safely and via the na... ver más

31/12/2024

Fraunhofer

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-08-18

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

MSCA-ITN-2020: Innovative Training Networks

I+D

Cerrada hace 4 años

0% 100%

10 Participantes

Fraunhofer

510.28K€ | Lider

FRUMECAR

296.26K€ | Participante

CENTRE FOR RESEARCH AND TECH...

144.26K€ | Participante

Últimas noticias

02-12-2024: AGENCIA-VALENCIANA-D... En las últimas 48 horas el Organismo AGENCIA VALENCIANA D... ha otorgado 1 concesiones

02-12-2024: CDTI En las últimas 48 horas el Organismo CDTI ha otorgado 4 concesiones

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

Duración del proyecto: 52 meses Fecha Inicio: 2020-08-18
Fecha Fin: 2024-12-31

Presupuesto del proyecto 3M€

Descripción del proyecto Bio2Brain aims to create a trans-European network of industrially oriented specialists fully trained and experienced, a significant driving force in innovating novel technologies to deliver biopharmaceuticals safely and via the nasal route of administration to the central nervous system (CNS). Diseases of the CNS and the spinal cord affect around 165 million Europeans with disorders such as Multiple Sclerosis, Alzheimer’s disease and Parkinson’s disease. CNS disorders are often connected with high morbidity, significant side effects, suffering of the patients and their families, as well as an enormous burden on the welfare systems. Therefore, in terms of social sustainability, Bio2Brain contributes to increased benefit for both, the society as whole and particularly for those individuals at a disadvantage through these disorders. A highly critical challenge of CNS diseases is the low central availability drugs in general and in particular of biopharmaceuticals like monoclonal antibodies (mAbs). Hence, approved medicinal products with a low CNS bioavailability are currently delivered via intrathecal, intracerebroventricular or intraparenchymal injections. In this way, they are delivered directly to the CNS. Unfortunately, such delivery systems are invasive, require a surgery with high risks, have a low patient compliance and are poorly controllable. Therefore, there is a critical need for a more safe and effective new approach, that means a paradigm shift, for drug delivery technologies in the treatment of CNS diseases. The Bio2Brain network will create a research environment for the interdisciplinary and intersectorial training of 13 ESRs supported by 11 academic teams (beneficiaries and partner universities), 6 key industrial stakeholders and an academic non-profit organization. As an important benefit, the close and frequent exposure of the ESRs to the private sector and to key technologies will significantly enhance their employability.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores